What is the role of activated protein C (drotrecogin alfa) for the treatment of disseminated intravascular coagulation (DIC)?

Updated: Dec 06, 2020
  • Author: Marcel M Levi, MD; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP  more...
  • Print
Answer

Administration of activated protein C (drotrecogin alfa) showed benefit in subgroups of patients with sepsis who have DIC, with consideration given to the anticoagulant effects of this agent. However, drotrecogin alfa was withdrawn from the worldwide market on October 25, 2011, after the PROWESS-SHOCK trial failed to show a survival benefit for patients with severe sepsis and septic shock. [73]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!